The current CDC report estimates that 1.3% of adults had myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on the most recent population based National Health Interview Survey (NHIS 2021–2022).
Dr. John Cush RheumNow
2 years 8 months ago
Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/AFoKm6kT86 https://t.co/dLTjTOdbmv
Dr. John Cush RheumNow
2 years 8 months ago
Watch: Non-TNFi b/tsDMARDs vs. TNFi in RA-ILD
https://t.co/fOz4jH58r9 https://t.co/jSHnsZscPg
Dr. John Cush RheumNow
2 years 8 months ago
Cardiology 101 for the Rheumatologist
Dr. Janet Pope reports on a cardiology session presented a 2023 ACR Convergence in San Diego, CA
https://t.co/0cS8JVneIG https://t.co/6SIPx6WmqX
Dr. John Cush RheumNow
2 years 8 months ago
FDA Warning on CAR-T Cell Therapy
The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
https://t.co/1OiMWJMskz https://t.co/8i8LFMcb1s
Dr. John Cush RheumNow
2 years 8 months ago
Full read BMJ ovverview of PMR
- PMR Clinically recognized 1957
- Is it a uniquie vs overlap entity
- Is there subclinical GCA in PMR?
- Is PMR for PCPs?
https://t.co/0BKGdt5Kxf https://t.co/sfAZoYyVan
Dr. John Cush RheumNow
2 years 8 months ago
ICYMI: How early is early in PsA?
Guidelines for the management of PsA recommend the early referral of patients with the suspected condition for early assessment and treatment.
https://t.co/AAZegiV6OL https://t.co/v5jIsPjX0c
Dr. John Cush RheumNow
2 years 8 months ago
Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/FJjdO27cQQ https://t.co/gis2aWOLa7
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
Dr. John Cush RheumNow
2 years 8 months ago
Early bird pricing has been extended! Register today!
https://t.co/BysC0RunUh https://t.co/4Ar0kHa4tt
Dr. John Cush RheumNow
2 years 8 months ago
Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now a report of 21 PPP pts given bimekizumab and 17 patients showed complete clearance in 1 to 4 months. SAPHO pts had complete clearance of skin & improved joint pain https://t.co/tYpHCxFOBI https://t.co/i4o3KnGlPY
